Salarius Pharmaceuticals Files 8-K on Operations and Equity Sales
Ticker: DCOY · Form: 8-K · Filed: Jan 17, 2025 · CIK: 1615219
Sentiment: neutral
Topics: operations, equity-sale
TL;DR
SALARIUS PHARMA FILES 8-K: UPDATE ON FINANCES & EQUITY SALES.
AI Summary
Salarius Pharmaceuticals, Inc. filed an 8-K on January 17, 2025, reporting on its results of operations and financial condition, as well as unregistered sales of equity securities as of January 13, 2025. The filing indicates the company's principal executive offices are located at 2450 Holcombe Blvd, Suite J-608, Houston, TX 77021.
Why It Matters
This filing provides investors with an update on Salarius Pharmaceuticals' financial status and any recent equity transactions, which are crucial for understanding the company's ongoing operations and potential dilution.
Risk Assessment
Risk Level: medium — The filing mentions unregistered sales of equity securities, which can sometimes indicate financial distress or dilutionary financing for the company.
Key Numbers
- 001-36812 — SEC File Number (Identifies the company's filing with the SEC)
- 46-5087339 — IRS Employer Identification Number (Company's tax identification number)
Key Players & Entities
- Salarius Pharmaceuticals, Inc. (company) — Registrant
- January 13, 2025 (date) — Earliest event reported
- January 17, 2025 (date) — Date of report
- 2450 Holcombe Blvd. Suite J-608, Houston, TX 77021 (location) — Principal executive offices
- Delaware (location) — State of incorporation
FAQ
What specific details are provided regarding the 'Results of Operations and Financial Condition'?
The filing does not provide specific details on the results of operations and financial condition within the provided text; it only states that these are items being reported on.
What type of 'Unregistered Sales of Equity Securities' occurred?
The provided text does not specify the nature or details of the unregistered sales of equity securities.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on January 13, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 2450 Holcombe Blvd. Suite J-608, Houston, TX 77021.
Has the company changed its name or former address recently?
The filing notes 'N/A' for former name or address changes since the last report, indicating no recent changes in these aspects.
Filing Stats: 678 words · 3 min read · ~2 pages · Grade level 12.1 · Accepted 2025-01-17 17:17:07
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 SLRX The Nasdaq Capital Market Indi
- $2.4 m — t its cash and cash equivalents totaled $2.4 million, which were held in bank deposit
- $3.50 — the purchase price paid by Investor was $3.50 per Purchase Share, for an aggregate pu
- $493,500 — are, for an aggregate purchase price of $493,500. The Company also issued 1,410 shares o
Filing Documents
- flks-20250113.htm (8-K) — 24KB
- 0001628280-25-001867.txt ( ) — 144KB
- flks-20250113.xsd (EX-101.SCH) — 2KB
- flks-20250113_lab.xml (EX-101.LAB) — 21KB
- flks-20250113_pre.xml (EX-101.PRE) — 12KB
- flks-20250113_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 17, 2025, Salarius Pharmaceuticals, Inc. (the "Company") disclosed that, as of December 31, 2024, the Company estimates that its cash and cash equivalents totaled $2.4 million, which were held in bank deposit accounts and a money market account. Such amounts are preliminary, have not been audited and are subject to change upon completion of the Company's audited financial statements for the year ended December 31, 2024. Additional information and disclosures would be required for a more complete understanding of the Company's financial position and results of operations as of December 31, 2024.
02 Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities. On January 13, 2025, the Company issued and sold 141,000 shares (the "Purchase Shares") of the Company's common stock, par value $0.0001 per share, to C/M Capital Master Fund, LP ("Investor"), pursuant to that certain Securities Purchase Agreement dated December 12, 2024, by and between Investor and the Company (the "Purchase Agreement"), as previously described in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on December 13, 2024. This issuance and sale was made following written notice delivered by the Company to Investor, directing Investor to purchase the Purchase Shares. Pursuant to the Purchase Agreement, the purchase price paid by Investor was $3.50 per Purchase Share, for an aggregate purchase price of $493,500. The Company also issued 1,410 shares of its common stock (the "Commitment Shares") to Investor as commitment shares pursuant to the terms of the Purchase Agreement. The issuance and sale of the Purchase Shares and the Commitment Shares is exempt from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Section 4(a)(2) thereof and/or Regulation D thereunder. The Company relied, in part, upon representations from Investor in the Purchase Agreement that Investor was an accredited investor as defined in Regulation D under the Securities Act. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SALARIUS PHARMACEUTICALS, INC. Date: January 17, 2025 By: /s/ Mark J. Rosenblum Mark J. Rosenblum Executive Vice President & Chief Financial Officer 3